Exclusive: Allergan shareholder Paulson & Co urges deal with Shire - sources
Reuters
Published Oct 20, 2014 12:23PM ET
Exclusive: Allergan shareholder Paulson & Co urges deal with Shire - sources
By Olivia Oran (Reuters) - Allergan Inc (N:AGN) shareholder Paulson & Co is urging the Botox maker to merge with specialty pharmaceutical company Shire Plc (L:SHP) as an alternative to a deal with hostile bidder Valeant Pharmaceuticals (TO:VRX), according to two people familiar with the matter.
The hedge fund told Allergan CEO David Pyott that it would support a deal with Shire, the sources said. The deal would not be structured as a so-called tax inversion, the people said.
It was not immediately clear whether Allergan would pursue such a deal. Allergan and Paulson declined to comment.
The move by Paulson, Allergan's third-largest shareholder, comes as AbbVie's (N:ABBV) $54 billion deal to buy Shire is close to unraveling after the U.S. government changed the rules governing tax inversions.
Shareholders including Paulson are looking at alternative strategies for Allergan as it tries to fend off a deal from Valeant. Some large Allergan shareholders have said they would prefer a deal with drugmaker Actavis Plc (N:ACT) to a tie-up with Shire.
Actavis plans to approach Allergan again about a potential merger, people previously told Reuters.
Paulson was also pushing behind the scenes for a deal between Allergan and Valeant earlier this summer, sources previously told Reuters. It remains unclear if the fund is still in favor of that.
Valeant might raise its bid for Allergan and would not abandon its pursuit ahead of a Dec. 18 special meeting, Michael Pearson, CEO of the Laval, Quebec-based company, said on Monday.
(Reporting by Olivia Oran in New York; Additional reporting by Nadia Damouni and Jessica Toonkel; Editing by Chizu Nomiyama and Lisa Von Ahn)
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.